Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENLV Enlivex Therapeutics	$1.78 +14.1%	$1.23	$0.81 ▼ $1.84	$36.90M	0.8	400,446 shs	922,024 shs
KPTI Karyopharm Therapeutics	$4.65 +4.5%	$4.32	$3.51 ▼ $16.95	$38.59M	0.28	148,293 shs	154,872 shs
OVID Ovid Therapeutics	$0.84 -2.1%	$0.44	$0.24 ▼ $1.47	$61.01M	0.2	2.79 million shs	2.63 million shs
SONN Sonnet BioTherapeutics	$3.76 -4.8%	$3.36	$1.08 ▼ $19.30	$12.51M	1.04	1.02 million shs	1.44 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENLV Enlivex Therapeutics	+14.10%	+31.85%	+44.72%	+78.00%	+42.40%
KPTI Karyopharm Therapeutics	+4.49%	+17.13%	+9.67%	-12.59%	-61.63%
OVID Ovid Therapeutics	-2.06%	+64.28%	+128.34%	+177.33%	-16.80%
SONN Sonnet BioTherapeutics	-4.81%	+30.56%	-61.51%	+191.47%	-34.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENLV Enlivex Therapeutics	2.8012 of 5 stars	3.7	3.0	0.0	3.0	0.8	0.6
KPTI Karyopharm Therapeutics	3.6507 of 5 stars	3.4	0.0	4.6	1.1	2.5	0.6
OVID Ovid Therapeutics	4.6706 of 5 stars	3.6	5.0	4.6	2.6	2.5	0.6
SONN Sonnet BioTherapeutics	2.6268 of 5 stars	3.5	2.0	0.0	2.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	461.80% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	631.18% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	268.92% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	431.91% Upside

Current Analyst Ratings Breakdown

Latest SONN, OVID, ENLV, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.28	N/A	N/A	($27.55) per share	-0.17
OVID Ovid Therapeutics	$570K	104.83	N/A	N/A	$0.96 per share	0.88
SONN Sonnet BioTherapeutics	$20K	595.96	N/A	N/A	($0.71) per share	-5.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-574.44%	-56.24%	-41.46%	N/A
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-965.23%	-294.91%	N/A

Latest SONN, OVID, ENLV, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENLV Enlivex Therapeutics	N/A	7.20	7.20
KPTI Karyopharm Therapeutics	N/A	0.99	1.28
OVID Ovid Therapeutics	0.22	4.93	4.93
SONN Sonnet BioTherapeutics	N/A	1.03	1.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENLV Enlivex Therapeutics	1.02%
KPTI Karyopharm Therapeutics	66.44%
OVID Ovid Therapeutics	72.24%
SONN Sonnet BioTherapeutics	9.45%

Insider Ownership

Company	Insider Ownership
ENLV Enlivex Therapeutics	12.28%
KPTI Karyopharm Therapeutics	2.98%
OVID Ovid Therapeutics	13.10%
SONN Sonnet BioTherapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
SONN Sonnet BioTherapeutics	10	3.17 million	3.10 million	Not Optionable

SONN, OVID, ENLV, and KPTI Headlines

Recent News About These Companies

Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Wednesday

August 12 at 2:47 AM | americanbankingnews.com

Sonnet Releases Virtual Investor "What This Means" Segment

August 11, 2025 | globenewswire.com

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

August 6, 2025 | msn.com

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

August 4, 2025 | globenewswire.com

Beyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury Assets

August 2, 2025 | msn.com

Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao

August 1, 2025 | tipranks.com

Solana-based treasury model goes global as DeFi Development launches franchise

July 17, 2025 | msn.com

WLFI tokens to become tradable after World Liberty holders’ vote

July 17, 2025 | msn.com

Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price

July 16, 2025 | cointelegraph.com

Sonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE Treasury

July 15, 2025 | thecurrencyanalytics.comT

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

July 15, 2025 | msn.com

Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal

July 14, 2025 | coinspeaker.com

Sonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.

July 14, 2025 | marketwatch.com

Why did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?

July 14, 2025 | tokenist.comT

Hyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrand

July 14, 2025 | fxstreet.com

HYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid Strategies

July 14, 2025 | msn.com

Massive deal sends biotech stock rallying 367%

July 14, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

July 14, 2025 | globenewswire.com

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

July 14, 2025 | benzinga.com

SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders

July 14, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SONN, OVID, ENLV, and KPTI Company Descriptions

Enlivex Therapeutics NASDAQ:ENLV

$1.78 +0.22 (+14.10%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.77 -0.01 (-0.34%)

As of 08/14/2025 07:58 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Karyopharm Therapeutics NASDAQ:KPTI

$4.65 +0.20 (+4.49%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.67 +0.02 (+0.43%)

As of 08/14/2025 07:57 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Ovid Therapeutics NASDAQ:OVID

$0.84 -0.02 (-2.06%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.83 -0.01 (-1.23%)

As of 08/14/2025 07:59 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sonnet BioTherapeutics NASDAQ:SONN

$3.76 -0.19 (-4.81%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.83 +0.07 (+1.97%)

As of 08/14/2025 08:00 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time